Health Secretary Robert F. Kennedy Jr. is set to unveil findings indicating a potential link between the use of an OTC pain reliever in pregnancy and a heightened risk of autism. The maker of Tylenol, KVUE, is experiencing a decline in stock value. Kennedy's report is expected to disclose research suggesting that a folate-based treatment could alleviate autism symptoms in some cases. The upcoming report from the Department of Health and Human Services is likely to spotlight insufficient folate levels and prenatal exposure to acetaminophen (Tylenol) as potential contributors to autism. For more details, visit Benzinga.com.